Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioQ Pharma Expands Agreement With Sandoz | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

BioQ Pharma Expands Agreement With Sandoz

Relates to U.S. license and supply agreement to commercialize third ready-to-use infusion product

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioQ Pharma has expanded its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready-to-use BioQ Pharma infusion pharmaceutical in the U.S. BioQ Pharma is responsible for developing and supplying the unit-dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product.

“We are pleased to grow our relationship with Sandoz, a leader in the pharmaceutical industry, with the addition of a third infusion product to our previously announced agreement. We believe that the presentation of this infusion pharmaceutical, AS-2, may provide important benefits for patients requiring sedation. Additionally, we believe that BioQ Pharma’s ready-to-use infusion system adds value by helping to lower the total cost of drug delivery,” said Josh Kriesel, president and chief executive officer, BioQ Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics